CA2438032C - Derives de benzothiazole et compositions et utilisations connexes - Google Patents

Derives de benzothiazole et compositions et utilisations connexes Download PDF

Info

Publication number
CA2438032C
CA2438032C CA2438032A CA2438032A CA2438032C CA 2438032 C CA2438032 C CA 2438032C CA 2438032 A CA2438032 A CA 2438032A CA 2438032 A CA2438032 A CA 2438032A CA 2438032 C CA2438032 C CA 2438032C
Authority
CA
Canada
Prior art keywords
compound
brain
amyloid
minutes
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2438032A
Other languages
English (en)
Other versions
CA2438032A1 (fr
Inventor
William E. Klunk
Chester A. Mathis, Jr.
Yanming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Priority to US10/645,847 priority Critical patent/US20050043523A1/en
Priority to CA2438032A priority patent/CA2438032C/fr
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Priority to PCT/US2004/007797 priority patent/WO2004083195A1/fr
Publication of CA2438032A1 publication Critical patent/CA2438032A1/fr
Application granted granted Critical
Publication of CA2438032C publication Critical patent/CA2438032C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention présente des composés dérivés de benzothiazole, les compositions comprenant de tels composés, des méthodes de préparation de tels composés et des méthodes d'utilisation de tels composés pour détecter les dépôts amyloïdes et diagnostiquer une maladie, un trouble ou un état caractérisés par des dépôts amyloïdes.
CA2438032A 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes Expired - Lifetime CA2438032C (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes
PCT/US2004/007797 WO2004083195A1 (fr) 2003-03-14 2004-03-15 Composes derives de benzothiazole, compositions et utilisations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
CA2438032A CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes

Publications (2)

Publication Number Publication Date
CA2438032A1 CA2438032A1 (fr) 2005-02-22
CA2438032C true CA2438032C (fr) 2013-05-07

Family

ID=34426453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2438032A Expired - Lifetime CA2438032C (fr) 2003-03-14 2003-08-22 Derives de benzothiazole et compositions et utilisations connexes

Country Status (2)

Country Link
CA (1) CA2438032C (fr)
WO (1) WO2004083195A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1587821T3 (da) 2002-12-19 2008-11-10 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af transthyretin og inhibering af transthyretin-fejlfolding
US7868033B2 (en) 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CN102973954A (zh) * 2004-07-02 2013-03-20 匹兹堡大学高等教育联邦体系 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
GB0516564D0 (en) 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
EP1937260A2 (fr) * 2005-09-16 2008-07-02 University of Pittsburgh Methode in vivo et in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene
ATE533485T1 (de) † 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
JP4738419B2 (ja) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
CN101351458A (zh) * 2005-12-01 2009-01-21 匹兹堡大学 作为促淀粉样变蛋白成像剂的同位素标记的苯并噻唑化合物
GB0525949D0 (en) 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
TW201018678A (en) * 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101636395A (zh) * 2007-03-06 2010-01-27 阿斯利康(瑞典)有限公司 新的2-杂芳基取代的吲哚695
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
WO2008134618A2 (fr) 2007-04-27 2008-11-06 The General Hospital Corporation Nouveaux marqueurs d'imagerie pour détecter et traiter précocement les plaques amyloïdes générées par la maladie d'alzheimer et des troubles associés
DK2182988T3 (da) * 2007-08-30 2014-05-26 Ge Healthcare Ltd Radiofarmaceutisk præparat
ITMC20080089A1 (it) * 2008-05-23 2008-08-22 Sparkle S R L Sintesi chimica di i-124[6-oh-bta-1-3'-i] iodine-124[2-(3'-iodo-4'-methylaminophenyl)-6-hydroxy-benzothialzole] per indagini pet e radioterapia.
JP2011524864A (ja) 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール
CA2737028C (fr) * 2008-09-23 2017-06-27 Wista Laboratories Ltd. Ligands pour molecules de la proteine tau agglomerees
AU2009309027A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
US9249112B2 (en) 2011-09-16 2016-02-02 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2014032732A1 (fr) 2012-08-28 2014-03-06 Eberhard Karls Universität Tübingen Medizinische Fakultät Benzoxazine halogénée et son utilisation
RU2671506C2 (ru) * 2013-09-26 2018-11-01 Ф. Хоффманн-Ля Рош Аг Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации
WO2015051188A1 (fr) * 2013-10-02 2015-04-09 Washington University Molécules hétérocycliques pour l'imagerie biomédicale et leurs applications thérapeutiques
SI3186233T1 (sl) 2014-08-29 2022-04-29 Chdi Foundation, Inc. Sonde za slikanje proteina huntingtina
EP3190888B1 (fr) 2014-08-29 2020-06-10 CHDI Foundation, Inc. Sondes d'imagerie de la protéine huntingtine
JP6485914B2 (ja) * 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
ES2536449T3 (es) * 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6696039B2 (en) * 2001-04-23 2004-02-24 Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents

Also Published As

Publication number Publication date
CA2438032A1 (fr) 2005-02-22
WO2004083195A1 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
CA2438032C (fr) Derives de benzothiazole et compositions et utilisations connexes
US9833458B2 (en) Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US9134328B2 (en) Methods of using benzothiazole derivative compounds and compositions
AU2011200667B2 (en) Benzothiazole derivative compounds, compositions and uses
US8343457B2 (en) Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies
AU2001286702A1 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
US20080286202A1 (en) Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition
US20050043523A1 (en) Benzothiazole derivative compounds, compositions and uses
JP2013507345A (ja) インビボイメージング剤としてのフルマゼニルの［１８ｆ］標識類似体

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230822